Plain-English translation of NCT06521866 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a medication called , an immune checkpoint inhibitor, combined with and other targeted drugs to treat advanced colorectal cancer. Researchers want to see if adding this immune-boosting medication to standard treatments can help patients live longer and control their cancer better. Some participants may also receive radiation therapy as part of their treatment plan.
Advanced colorectal cancer that has spread to other parts of the body or cannot be surgically removed is difficult to treat with existing therapies alone. This medication works by helping the body's immune system recognize and fight cancer cells, and researchers believe combining it with may be more effective than alone.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous (IV) infusions of the medication and drugs every two weeks during an initial treatment phase lasting several months, followed by ongoing maintenance therapy. Depending on which study group you're assigned to, you may also receive focused radiation therapy. Throughout the trial, you would have regular blood tests, imaging scans, and clinic visits to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China